Vaccinex, Inc., a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs.
+ 2 more risks
Limited growth with worrying balance sheet.
Share Price & News
How has Vaccinex's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: VCNX's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: VCNX underperformed the US Biotechs industry which returned 24.5% over the past year.
Return vs Market: VCNX underperformed the US Market which returned 8.4% over the past year.
Price Volatility Vs. Market
How volatile is Vaccinex's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 year ago | Simply Wall StDo Directors Own Vaccinex, Inc. (NASDAQ:VCNX) Shares?
1 year ago | Simply Wall StIs Vaccinex Inc (NASDAQ:VCNX) A Financially Sound Company?
1 year ago | Simply Wall StIs Vaccinex Inc (NASDAQ:VCNX) On The Right Side Of Disruption?
Is Vaccinex undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Vaccinex is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Vaccinex has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
- Take a look at our analysis of VCNX’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.
How is Vaccinex forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VCNX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: VCNX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: VCNX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: VCNX's revenue (77.7% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: VCNX's revenue (77.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if VCNX's Return on Equity is forecast to be high in 3 years time
How has Vaccinex performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VCNX is currently unprofitable.
Growing Profit Margin: VCNX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: VCNX is unprofitable, and losses have increased over the past 5 years at a rate of -11.2% per year.
Accelerating Growth: Unable to compare VCNX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VCNX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: VCNX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Vaccinex's financial position?
Financial Position Analysis
Short Term Liabilities: VCNX has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: VCNX has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: VCNX is debt free.
Reducing Debt: VCNX's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VCNX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: VCNX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 16% each year
What is Vaccinex's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate VCNX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate VCNX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VCNX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VCNX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of VCNX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Maurice Zauderer (73yo)
Dr. Maurice Zauderer, Ph.D. Co-Founded Vaccinex, Inc. in April 2001 and also serves as its President and Chief Executive Officer since April 2001. Dr. Zauderer serves as Director of Vaccinex Inc. since Apr ...
CEO Compensation Analysis
Compensation vs Market: Maurice's total compensation ($USD398.87K) is below average for companies of similar size in the US market ($USD587.77K).
Compensation vs Earnings: Maurice's compensation has increased whilst the company is unprofitable.
|Senior VP & COO||14.33yrs||US$263.24k||0.047% $29.6k|
|Senior VP of Research & Chief Scientific Officer||11.42yrs||US$263.24k||0.048% $30.2k|
|Co-Founder||no data||no data||no data|
|Chief Financial Officer||2.25yrs||no data||0.024% $15.1k|
|Senior Vice President of Development||11.33yrs||no data||0.0061% $3.8k|
Experienced Management: VCNX's management team is seasoned and experienced (11.4 years average tenure).
|Co-Founder||no data||no data||no data|
|Independent Director||15.42yrs||US$75.00k||no data|
|Independent Director||17.17yrs||US$90.00k||no data|
|Independent Director||7yrs||US$82.50k||0.0018% $1.1k|
|Member of Scientific & Clinical Advisory Board||no data||no data||no data|
|Scientific and Clinical Advisor||no data||no data||no data|
|Chairman of the Board||19.08yrs||no data||2.64% $1.7m|
|Independent Director||5.25yrs||US$85.00k||no data|
|Independent Lead Director||no data||US$75.00k||0.32% $199.3k|
Experienced Board: VCNX's board of directors are seasoned and experienced ( 16.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 45%.
Vaccinex, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Vaccinex, Inc.
- Ticker: VCNX
- Exchange: NasdaqCM
- Founded: 2001
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$62.747m
- Shares outstanding: 16.64m
- Website: https://www.vaccinex.com
Number of Employees
- Vaccinex, Inc.
- 1895 Mount Hope Avenue
- New York
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|VCNX||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Aug 2018|
Vaccinex, Inc., a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), Huntington’s disease, osteosarcoma, melanoma, and Alzheimer’s disease. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and potentially for other autoimmune disorders; and VX25, a bi-specific natural killer T (NKT) cell stimulator, for the therapeutic application of NKT cell stimulation for cancer immunotherapy. It has a clinical trial collaboration and supply agreement with Merck KGaA to test pepinemab in combination with avelumab checkpoint inhibitor in NSCLC patients. Vaccinex, Inc. was founded in 2001 and is headquartered in Rochester, New York.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/28 04:13|
|End of Day Share Price||2020/05/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.